Hypertension, Vol 17, 643-651, Copyright © 1991 by American Heart Association
CJ Charles, EA Espiner, VA Cameron, AM Richards, TG Yandle and EJ Sybertz
Whole body clearance of atrial natriuretic factor is due to both receptor
uptake and enzymatic degradation initiated by neutral endopeptidase 24.11.
The effects of neutral endopeptidase inhibition have been studied in seven
sodium-replete sheep using SCH 39370, a specific and potent inhibitor of
neutral endopeptidase, in the presence or absence of exogenous hormone [rat
ANF-(101-126), 2.4 pmol/kg/min for 2 hours]. SCH 39370 alone (2.5 mg/kg
bolus) increased plasma atrial natriuretic factor and plasma cyclic GMP
levels, lowered arterial pressure for periods beyond changes in plasma
atrial natriuretic factor or cyclic GMP, and suppressed both plasma
aldosterone and cortisol levels when compared with vehicle injections. The
effects of SCH 39370 were similar to or exceeded those of atrial
natriuretic factor infusions, which induced significantly greater increases
in plasma atrial natriuretic factor (p = 0.01). Neither agent alone was
natriuretic. When SCH 39370 and atrial natriuretic factor were given
together, plasma cyclic GMP but not atrial natriuretic factor levels were
increased (p = 0.013) compared with atrial natriuretic factor infusion
alone, and the half-life was prolonged (p = 0.002) in the presence of SCH
39370. The hypotensive response was greater than that induced by atrial
natriuretic factor alone (p = 0.03) but not different from SCH 39370 alone.
Inhibitory effects of SCH 39370 on aldosterone levels were similar in the
presence of absence of exogenous atrial natriuretic factor.(ABSTRACT
TRUNCATED AT 250 WORDS)
ARTICLES
Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep
Department of Endocrinology, Princess Margaret Hospital, Christchurch, New Zealand.
This article has been cited by other articles:
![]() |
M. W. TAAL, V. D. NENOV, W. WONG, S. R. SATYAL, O. SAKHAROVA, J. H. CHOI, J. L. TROY, and B. M. BRENNER Vasopeptidase Inhibition Affords Greater Renoprotection than Angiotensin-Converting Enzyme Inhibition Alone J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2051 - 2059. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Charles, E. A. Espiner, A. M. Richards, and E. J. Sybertz Endopeptidase Inhibition in Angiotensin-Induced Hypertension : Effect of SCH 39370 in Sheep Hypertension, July 1, 1995; 26(1): 89 - 94. [Abstract] [Full Text] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1991 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |